Abbvie Inc. (United States) holds 7 active US FDA Type II Drug Master Files and 8 inactive, has DMF or CEP filings on record for 13 active ingredients and is linked to 12 FDA-registered manufacturing sites. 18 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Abbvie Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/abbvie-inc

Overview

AbbVie Inc. is a global, research-based biopharmaceutical company that develops and markets therapies for serious health challenges. Known for its innovative approach, AbbVie focuses on areas including immunology, oncology, virology, and neuroscience.

Core services & business areas

Biologics ManufacturingSmall Molecule ManufacturingFormulation DevelopmentAnalytical ServicesPackaging

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Abbvie Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Abbvie Inc. holds 7 active (15 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • ERYTHROMYCIN BASEActive2015-11-10
  • PARICALCITOL DRUG SUBSTANCEActive2010-11-30
  • ERYTHROMYCIN STEARATEActive1998-09-01
  • CYCLOSPORINE USPActive1998-09-01
  • ERYTHROMYCIN ETHYLSUCCINATEActive1998-09-01
  • ERYTHROMYCIN BASEActive1998-04-30
  • BUTORPHANOL TARTRATEActive1990-12-20
  • NIACIN CORE TABLET INTERMEDIATEInactive2008-10-31
  • CHOLINE FENOFIBRATE MINI-TABLET INTERMEDIATEInactive2007-11-13
  • CHOLINE FENOFIBRATE DRUG SUBSTANCEInactive2007-11-13
  • 5-DESOSAMINYL-6-0-METHYL ERYTHRONOLIDEInactive1999-12-22
  • ERYTHROMYCIN BASEInactive1998-09-01
  • CLINDAMYCIN PHOSPHATEInactive1998-09-01
  • CLORAZEPATE DIPOTASSIUM (TRANXENE)Inactive1982-05-07
  • PRAMOXINE HCLInactive1982-04-30

Registered manufacturing sites (12)

Physical sites registered with the US FDA and resolved to Abbvie Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

18 FDA enforcement records linked to this company.

  • recall — Class III2026-06-03

    Failed Stability Specifications

  • recall — Class II2024-10-02

    Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

  • recall — Class II2024-10-02

    Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

  • recall — Class III2023-11-15

    Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

  • 4832018-07-02

    Late submission of 15-day report

  • recall — Class III2018-02-07

    Defective container: presence of a hole in the liners of the caps covering the product bottle, introducing possibility of leakage.

  • recall — Class III2017-11-01

    Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

  • recall — Class III2017-11-01

    Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.

  • recall — Class II2017-03-08

    Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life

  • recall — Class III2016-04-27

    Failed Content Uniformity Specifications

  • 4832015-08-06

    Procedures to be written and followed

  • recall — Class II2014-10-08

    Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

  • recall — Class II2014-05-07

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

  • recall — Class II2014-05-07

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

  • recall — Class II2014-05-07

    Defective Delivery System: Some Lupron Depot Kits may containin a syringe with a potentially defective LuproLoc needle stick protection device.

  • recall — Class II2014-05-07

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

  • recall — Class II2014-05-07

    Defective Delivery System: Some Lupron Depot Kits may contain a syringe with a potentially defective LuproLoc needle stick protection device.

  • recall — Class III2013-08-28

    Labeling: Incorrect Package Insert; product packaged with outdated version of the insert

For suppliers

Is this Abbvie Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.